Capricor Stock Drops 13% After Suing Partner NS Pharma

Key Developments

Capricor Therapeutics (NASDAQ:CAPR) shares plunged 13% after the company filed a lawsuit against its distribution partner, Nippon Shinyaku Co., Ltd., and its U.S. subsidiary NS Pharma Inc. The legal action has raised significant concerns among investors about the partnership's future.

Overview of the Situation

The dispute centers on the commercial distribution agreement for Deramiocel, an investigational cell therapy for Duchenne muscular dystrophy. Capricor alleges that NS Pharma failed to adequately prepare for a commercial launch and claims a pricing mechanism in their agreement would prevent patient access through Medicare, Medicaid, or private insurance.

Impact on the Market

The lawsuit triggered a sharp sell-off for both companies. In addition to Capricor's 13% decline, Nippon Shinyaku's shares fell by as much as 15%. This reflects market uncertainty regarding the future commercialization of Deramiocel, a key asset for Capricor pending FDA approval.

Summary

Capricor is seeking to rescind the distribution agreement and is preparing its own commercial launch plans. The Food and Drug Administration has granted Deramiocel Priority Review with a target action date of August 22, 2026. The outcome of this legal battle will be a critical factor for the therapy's market entry.

FAQ

Q: Why did Capricor Therapeutics stock fall?
A: The stock dropped 13% after the company sued its distribution partner, NS Pharma, over the commercial agreement for its drug, Deramiocel.

Q: What is Deramiocel?
A: It is an investigational cell therapy developed for treating Duchenne muscular dystrophy, a progressive and fatal genetic disorder.

Source: Investing.com